Inventor
BHASKAR VINAY
US39 patents
⚠️ This page may combine multiple inventors who share the name “BHASKAR VINAY”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
WEREWOLF THERAPEUTICS INC
9 patentsUS10696723B2Jun 30, 2020
Activatable interleukin 12 polypeptides
WEREWOLF THERAPEUTICS INC15 citations93
US10696724B2Jun 30, 2020
Activatable interleukin-2 polypeptides
WEREWOLF THERAPEUTICS INC18 citations93
US11352403B2Jun 7, 2022
Activatable interleukin-2 polypeptides and methods of use thereof
WEREWOLF THERAPEUTICS INC6 citations84
US11981716B2May 14, 2024
Activatable interleukin-2 polypeptides and methods of use thereof
WEREWOLF THERAPEUTICS INC2 citations72
US11535658B2Dec 27, 2022
Activatable interleukin-2 polypeptides and methods of use thereof
WEREWOLF THERAPEUTICS INC2 citations72
US12534505B2Jan 27, 2026
Activatable interleukin-2 polypeptides and methods of use thereof
WEREWOLF THERAPEUTICS INC0 citations61
US12275769B2Apr 15, 2025
Activatable interleukin 12 polypeptides and methods of use thereof
WEREWOLF THERAPEUTICS INC0 citations61
US11453710B2Sep 27, 2022
Activatable interleukin 12 polypeptides and methods of use thereof
WEREWOLF THERAPEUTICS INC0 citations61
US11739132B2Aug 29, 2023
Separation moieties and methods of use thereof
WEREWOLF THERAPEUTICS INC0 citations57
FACET BIOTECH CORP
8 patentsUS7662384B2Feb 16, 2010
Use of anti-α5β1 antibodies to inhibit cancer cell proliferation
FACET BIOTECH CORP21 citations89
US7807163B2Oct 5, 2010
Antibodies against GPR64 and uses thereof
FACET BIOTECH CORP7 citations73
US7824678B2Nov 2, 2010
Antibodies against cancer antigen TMEFF2 and uses thereof
FACET BIOTECH CORP4 citations72
US7674883B2Mar 9, 2010
Antibodies against cancer antigen TMEFF2 and uses thereof
FACET BIOTECH CORP6 citations72
US7785816B2Aug 31, 2010
Antibodies against cancer antigen TMEFF2 and uses thereof
FACET BIOTECH CORP2 citations61
US7879987B2Feb 1, 2011
Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
FACET BIOTECH CORP0 citations51
US7776585B2Aug 17, 2010
Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
FACET BIOTECH CORP0 citations51
US7547544B2Jun 16, 2009
Antibodies against GPR64 and uses thereof
FACET BIOTECH CORP0 citations51
TAKEDA PHARMACEUTICALS CO
7 patentsUS10494444B2Dec 3, 2019
Anti-CD38 antibodies
TAKEDA PHARMACEUTICALS CO8 citations92
US10336833B2Jul 2, 2019
Conjugated anti-CD38 antibodies
TAKEDA PHARMACEUTICALS CO9 citations92
US9676869B2Jun 13, 2017
Conjugated anti-CD38 antibodies
TAKEDA PHARMACEUTICALS CO12 citations92
US9790285B2Oct 17, 2017
Anti-CD38 antibodies
TAKEDA PHARMACEUTICALS CO7 citations83
US12312411B2May 27, 2025
Anti-CD38 binding domains
TAKEDA PHARMACEUTICALS CO0 citations62
US12209138B2Jan 28, 2025
Anti-CD38 antibodies
TAKEDA PHARMACEUTICALS CO0 citations62
US11434304B2Sep 6, 2022
Anti-CD38 antibodies
TAKEDA PHARMACEUTICALS CO0 citations62
PDL BIOPHARMA INC
3 patentsUS7276372B2Oct 2, 2007
Antibodies against GPR64 and uses thereof
PDL BIOPHARMA INC12 citations92
US7288248B2Oct 30, 2007
Antibodies against cancer antigen TMEFF2 and uses thereof
PDL BIOPHARMA INC27 citations91
US7276589B2Oct 2, 2007
Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
PDL BIOPHARMA INC23 citations91